Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Black Diamond Therapeutics (BDTX – Research Report). The ...
Black Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 In Patients With NSCLC
Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or ...
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...
Black Diamond reports encouraging Phase 2 data for BDTX-1535
Black Diamond Therapeutics (NASDAQ:BDTX) reported encouraging Phase 2 data for its drug candidate BDTX-1535 in the treatment ...
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that ...
Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment
Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
FierceBiotech1d
Black Diamond, Ideaya entertain registrational trial ideas as cancer drugs show midstage promise
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
Yahoo Finance1d
HusCompagniet A/S (HCE.DU)
Workers already have asked it more than 500,000 questions. BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed ...
Investing14d
Black Diamond shares target reiterated, overweight rating on recent updates
These results are seen as setting benchmarks for Black Diamond's BDTX-1535, particularly in its ongoing first-line non-classical cohort. The targeted outcomes for BDTX-1535 include an objective ...
Investing14d
Black Diamond shares target reiterated, overweight rating on recent updates
These results are seen as setting benchmarks for Black Diamond's BDTX-1535, particularly in its ongoing first-line non-classical cohort. The targeted outcomes for BDTX-1535 include an objective ...
Investing8d
Piper Sandler maintains Overweight rating on Black Diamond Therapeutics shares
This finding could present a new first-line treatment opportunity for Black Diamond Therapeutics' drug candidate, BDTX-1535, in treating EGFR non-small cell lung cancer (NSCLC). In other recent ...
Investing8d
Piper Sandler maintains Overweight rating on Black Diamond Therapeutics shares
This finding could present a new first-line treatment opportunity for Black Diamond Therapeutics' drug candidate, BDTX-1535, in treating EGFR non-small cell lung cancer (NSCLC). In other recent news, ...